Evalution of glucose lowering efficacy between Dipeptidyl Peptidase-4 inhibitors (DPP-4) and Sodium-Glucose cotransporter-2 inhibitors (SGLT-2) in type 2 diabetes mellitus patients at Hospital

Abstract

    In Viet Nam, the use of SGLT-2 inhibitors and DPP-4 inhibitors in patients with type 2 diabetes is limited. The study was conducted to evaluate the treatment efficacy between SGLT-2 inhibitors and DPP-4 inhibitors on blood sugar control. Descriptive cross-sectional study, 6-month follow-up was performed in type 2 diabetes patients from January 2024 to June 2024 at Nhan Dan Gia Dinh Hospital. Results have shown that over 80 % of patients were treated with metformin combination therapy. The most commonly prescribed active ingredient in the SGLT-2 inhibitor group is Empagliflozin with 70.40 %, followed by Dapagliflozin with 29.60 %. The most commonly prescribed active ingredient in the DPP-4 inhibitor group is Sitagliptin with 65.00 %, followed by Vildagliptin with 23.30% and Linagliptin with 11.70 %. The difference in glycemic control and HbA1c reduction after 6 months was not statistically significant between the SGLT-2 inhibitor group and the DPP-4 inhibitor group ((1.20 ± 0.80) % vs (1.10 ± 0.70) %, respectively, p > 0.05). Both groups showed effectiveness in controlling blood sugar in patients and did not increase the risk of hypoglycemia. There is a relationship between blood sugar and cardiovascular outcomes in type 2 diabetic patients.